Antitumor mechanism of kaempferol

doi:10.3760/cma.j.issn.1673-422X.2013.12.004

Abstract

Abstract: Kaempferol is a kind of flavonoid compound that exists in natural plants including fruits, vegetables and Chinese herbal medicine. Kaempferol has extensive pharmacological activities, including antitumor, antioxidant, antiinflammatory, anxiolytic, analgesic and antiallergic activities. Researches show that Kaempferol can reduce the risk of cancer, can inhibit proliferation and invasion of tumor cells by inducing apoptosis, regulating cell cycle, inhibiting angiogenesis and tumor metastasis. Meanwhile, kaempferol can suppress tumor growth by regulating the oxidative stress reaction and inhibiting inflammatory cytokines. In a word, kaempferol has broad prospects in cancer prevention and treatment.

Key words: Kaempferols, Neoplasms, Apoptosis, Cell cycle

FU Cheng-Rui, LI Bao-Sheng. Antitumor mechanism of kaempferol[J]. Journal of International Oncology, 2013, 40(12): 892-895.

References

［1］ Li W, Du B, Wang T, et al. Kaempferol induces apoptosis in human HCT116 colon cancer cells via the AtaxiaTelangiectasia Mutatedp53 pathway with the involvement of p53 Upregulated Modulator of Apoptosis. Chem Biol Interact, 2009, 177(2): 121127. ［2］ Zhang Q, Zhao XH, Wang ZJ. Cytotoxicity of flavones and flavonols to a human esophageal squamous cell carcinoma cell line (KYSE510) by induction of G2/M arrest and apoptosis. Toxicol In Vitro, 2009, 23(5): 797807. ［3］ Kang GY, Lee ER, Kim JH, et al. Downregulation of PLK1 expression in kaempferolinduced apoptosis of MCF7 cells. Eur J Pharmacol, 2009, 611(13): 1721. ［4］ Marfe G, Tafani M, Indelicato M, et al. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J Cell Biochem, 2009, 106(4): 643650. ［5］ Huang WW, Tsai SC, Peng SF, et al. Kaempferol induces autophagy through AMPK and AKT signaling molecules and causes G2/M arrest via downregulation of CDK1/cyclin B in SKHEP1 human hepatic cancer cells. Int J Oncol, 2013, 42(6): 20692077. ［6］ Luo H, Daddysman MK, Rankin GO, et al. Kaempferol enhances cisplatin′s effect on ovarian cancer cells through promoting apoptosis caused by down regulation of cMyc. Cancer Cell Int, 2010, 10: 16. ［7］ Luo H, Rankin GO, Li Z, et al. Kaempferol induces apoptosis in ovarian cancer cells through activating p53 in the intrinsic pathway. Food Chem, 2011, 128(2): 513519. ［8］ Ria R, Reale A, De Luisi A, et al. Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res, 2011, 1(1): 7689. ［9］ Luo H, Rankin GO, Juliano N, et al. Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERKNFkappaBcMycp21 pathway. Food Chem, 2012, 130(2): 321328. ［10］ Luo H, Rankin GO, Liu L, et al. Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer, 2009, 61(4): 554563. ［11］ HadlerOlsen E, Winberg JO, UhlinHansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol, 2013, 34(4): 20412051. ［12］ Phromnoi K, Yodkeeree S, Anuchapreeda S, et al. Inhibition of MMP3 activity and invasion of the MDAMB231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol Sin, 2009, 30(8): 11691176. ［13］ Labbe D, Provencal M, Lamy S, et al. The flavonols quercetin, kaempferol, and myricetin inhibit hepatocyte growth factorinduced medulloblastoma cell migration. J Nutr, 2009, 139(4): 646652. ［14］ LópezLázaro M. A new view of carcinogenesis and an alternative approach to cancer therapy. Mol Med, 2010, 16(34): 144153. ［15］ Lee S, Kim YJ, Kwon S, et al. Inhibitory effects of flavonoids on TNFalphainduced IL8 gene expression in HEK 293 cells. BMB Rep, 2009, 42(5): 265270. ［16］ Seibert H, Maser E, Schweda K, et al. Cytoprotective activity against peroxideinduced oxidative damage and cytotoxicity of flavonoids in C6 rat glioma cells. Food Chem Toxicol, 2011, 49(9): 23982407. ［17］ Nirmala P， Ramanathan M. Effect of kaempferol on lipid peroxidation and antioxidant status in 1,2dimethyl hydrazine induced colorectal carcinoma in rats. Eur J Pharmacol, 2011, 654(1): 7579. ［18］ Mantovani A, Allavena P, Sica A, et al. Cancerrelated inflammation. Nature, 2008, 454(7203): 436444. ［19］ Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin8 expressionmediated inflammation and angiogenesis. Int J Inflam, 2011, 2011: 908468. ［20］ Chen SS, Michael A, ButlerManuel SA. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med, 2012, 13(68): 717. ［21］ Mukai R, Satsu H, Shimizu M, et al. Inhibition of Pglycoprotein enhances the suppressive effect of kaempferol on transformation of the aryl hydrocarbon receptor. Biosci Biotechnol Biochem, 2009, 73(7): 16351639. ［22］ Wang H, Gao M, Wang J. Kaempferol inhibits cancer cell growth by antagonizing estrogenrelated receptor alpha and gamma activities. Cell Biol Int, 2013, In press. ［23］ To KK, Yu L, Liu S, et al. Constitutive AhR activation leads to concomitant ABCG2mediated multidrug resistance in cisplatinresistant esophageal carcinoma cells. Mol Carcinog, 2012, 51(6): 449464. ［24］ Nakatsuma A, Fukami T, Suzuki T, et al. Effects of kaempferol on the mechanisms of drug resistance in the human glioblastoma cell line T98G. Pharmazie, 2010, 65(5): 379383. ［25］ Ahmed F, Toume K, Ohtsuki T, et al. Cryptolepine, isolated from Sida acuta, sensitizes human gastric adenocarcinoma cells to TRAILinduced apoptosis. Phytother Res, 2011, 25(1): 147150. ［26］ Geybels MS, Verhage BA, Arts IC, et al. Dietary flavonoid intake, black tea consumption, and risk of overall and advanced stage prostate cancer. Am J Epidemiol, 2013, 177(12): 13881398. ［27］ Bobe G, Albert PS, Sansbury LB, et al. Interleukin6 as a potential indicator for prevention of highrisk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila), 2010, 3(6): 764775. ［28］ Gates MA, Vitonis AF, Tworoger SS, et al. Flavonoid intake and ovarian cancer risk in a populationbased casecontrol study. Int J Cancer, 2009, 124(8): 19181925. ［29］ Simons CC, Hughes LA, Arts IC, et al. Dietary flavonol, flavone and catechin intake and risk of colorectal cancer in the Netherlands Cohort Study. Int J Cancer, 2009, 125(12): 29452952. ［30］ Wang L, Lee IM, Zhang SM, et al. Dietary intake of selected flavonols, flavones, and flavonoidrich foods and risk of cancer in middleaged and older women. Am J Clin Nutr, 2009, 89(3): 905912.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.